cas 2252415-10-2|| where to buy potassium;trifluoro-(2-fluoro-6-hydroxyphenyl)boranuide

製品名:potassium;trifluoro-(2-fluoro-6-hydroxyphenyl)boranuide

IUPAC Name:potassium trifluoro(2-fluoro-6-hydroxyphenyl)boranuide

包装単位	有効在庫	価格（USD）
CM327541-50g	in stock	ŵǜǶȡ
CM327541-100g	in stock	ǶŵũȺ
CM327541-1000g	in stock	ƦǜũƦ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2252415-10-2 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2252415-10-2; 分子式:C6H4BF4KO; 融点:-; SMILESコード:OC1=C([B-](F)(F)F)C(F)=CC=C1.[K+]; 密度:

: Sotorasib; Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.

: MK-1084; Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.